BMS Chooses Houston for $2.3B Manufacturing Facility
Among key factors in the decision, according to BMS, were the emerging strength of Greater Houston’s life sciences workforce in life sciences, proximity to utilities and transportation infrastructure, an overall business climate conducive to long-term growth—and available incentives. The post BMS Chooses Houston for $2.3B Manufacturing Facility appeared first on GEN - Genetic Engineering and…
Bristol Myers Squibb (BMS) has announced plans to build a $2.3 billion multi-modal manufacturing campus in Houston. The site, which will be situated within Generation Park, a 4,300-acre master planned complex, will support the production of multiple types of treatments such as small molecules, biologics, and antibody-drug conjugates (ADCs) across various disease areas.
This investment aligns with BMS' broader commitment to allocate $40 billion over five years to U.S.-based R&D, technology, and manufacturing. CEO Christopher Boerner highlighted the company's confidence in America's continued leadership in biopharmaceutical innovation, stressing the importance of building domestic manufacturing capabilities to deliver future medicines and support scientific breakthroughs.
Houston and Texas were chosen due to their talent pool, infrastructure, and potential partnerships. BMS' modular campus design allows for easy scaling and reconfiguration to meet evolving needs. The company anticipates creating nearly 500 skilled jobs at the site, with around 2,000 construction and indirect jobs generated during its construction.
Texas has pledged a $4.89 million grant to BMS and designated the facility as eligible for incentives through its JETI program. The state boasts a robust life sciences ecosystem, including the Texas Medical Center, six medical schools, three Tier One research universities, and specialized biotech training programs. BioHouston estimates the region has attracted about $500 million in venture capital funding from 2025 to mid-2026, reinforcing Houston's appeal as a destination for life sciences and advanced manufacturing.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
